The Medicines Co. may have prospectively eased the pain of generic competition that looms for flagship product Angiomax (bivalirudin) – and may have helped stanch the money hemorrhage that would result – by winning FDA approval of two drug-device combo therapies: one for patients who need opioid analgesia in the hospital and another to control bleeding.
"Casting a wide net" with its phase I trial testing MRX34, Mirna Therapeutics Inc. raked in $41.8 million by way of a series D financing that will enable a phase II experiment in the first half of next year, in a cancer indication yet to be decided upon, CEO Paul Lammers told BioWorld Today.
Resverlogix Corp. CEO Donald McCaffrey told BioWorld Asia he is "very confident" about collecting the potential $400 million-plus from a licensing deal in China, Hong Kong, Taiwan and Macau with Shenzhen Hepalink Pharmaceutical Co. Ltd., centered on RVX-208, a late-stage, first-in-class, small-molecule BET bromodomain inhibitor. "We downplayed the number," he said.
Having banked $38 million in a series A round late last year, cancer immunotherapy firm Potenza Therapeutics Inc. is "in good shape in terms of financing," thanks also to an undisclosed amount of new money from a deal with Astellas Pharma Inc., CEO Daniel Hicklin told BioWorld Asia.
On schedule, Biomarin Pharmaceutical Inc. this week finished off the rolling new drug application (NDA) for exon 51-skipping drisapersen to treat Duchenne muscular dystrophy (DMD), situating the firm a few months ahead of Sarepta Therapeutics Inc. with eteplirsen, another exon 51 DMD therapy.
Resverlogix Corp. CEO Donald McCaffrey told BioWorld Today he is "very confident" about collecting the potential $400 million-plus from a licensing deal in China, Hong Kong, Taiwan, and Macau with Shenzhen Hepalink Pharmaceutical Co. Ltd., centered on RVX-208, a late-stage, first-in-class, small-molecule BET bromodomain inhibitor. "We downplayed the number," he said.
Aerie Pharmaceuticals Inc.'s stock took a dizzying hit on word of its phase III failure in Rocket 1 with once-daily eye drop Rhopressa for intra-ocular pressure (IOP) in glaucoma, while shares of another player in the space, Inotek Pharmaceuticals Inc., added value in Wall Street's eyes.
Fluorine-focused Scifluor Life Sciences Inc. pulled down $30 million that should "allow us to get into what we suspect will be four phase I trials" with a pair of compounds – including eye drops for age-related macular degeneration (AMD) – and provides "at least a two-year runway," CEO Omar Amirana told BioWorld Today.
